Quoin Pharmaceuticals, Ltd.
QNRX
$6.69
$0.09141.39%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.64% | -0.64% | -1.05% | -4.06% | -5.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.45% | 18.95% | -5.44% | -11.43% | 6.32% |
| Operating Income | -8.45% | -18.95% | 5.44% | 11.43% | -6.32% |
| Income Before Tax | -12.75% | -21.97% | 6.31% | 10.60% | -2.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.75% | -21.97% | 6.31% | 10.60% | -2.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.75% | -21.97% | 6.31% | 10.60% | -2.44% |
| EBIT | -8.45% | -18.95% | 5.44% | 11.43% | -6.32% |
| EBITDA | -8.58% | -19.24% | 5.46% | 11.50% | -6.41% |
| EPS Basic | 82.98% | 76.16% | 81.68% | 72.91% | 58.09% |
| Normalized Basic EPS | 82.98% | 76.16% | 81.68% | 72.91% | 58.09% |
| EPS Diluted | 82.92% | 75.92% | 81.68% | 72.91% | 58.08% |
| Normalized Diluted EPS | 82.98% | 76.16% | 81.68% | 72.91% | 58.09% |
| Average Basic Shares Outstanding | 562.77% | 411.70% | 411.70% | 230.22% | 145.22% |
| Average Diluted Shares Outstanding | 562.50% | 412.50% | 412.50% | 240.00% | 166.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |